S&P Futures
5,993.75 -12.75 (-0.21%) Dow Futures
44,749.00 -77.00 (-0.17%) Nasdaq Futures
20,834.00 -46.25 (-0.22%) Russell 2000 Futures
2,434.70 -16.30 (-0.67%) Crude Oil
68.84 -0.10 (-0.15%) Gold
2,630.20 +11.70 (+0.45%)
Diamyd Medical AB (publ) (DMYD-B.ST)
| Previous Close | 12.60 |
| Open | 12.60 |
| Bid | 12.92 x 0 |
| Ask | 13.04 x 0 |
| Day's Range | 12.60 - 13.28 |
| 52 Week Range | 6.41 - 25.00 |
| Volume | |
| Avg. Volume | 167,812 |
| Market Cap | 1.345B |
| Beta (5Y Monthly) | 2.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.60 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.00 |
PR NewswireDiamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes
Diamyd Medical today announced a successful interim analysis (non-futility test) for its ongoing precision medicine Phase 3 DIAGNODE-3 trial. The interim analysis, reviewed by an independent Data Safety Monitoring Board (DSMB), resulted in a favorable recommendation to continue the trial without any modifications.
PR NewswireDiamyd Medical receives second U.S. FDA Fast Track designation for Diamyd® - for the prevention of Type 1 Diabetes
Diamyd Medical announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd® (rhGAD65/alum) to treat Type 1 Diabetes in pediatric patients with Stage 1 or Stage 2 Type 1 Diabetes carrying the genotype HLA DR3-DQ2. Earlier this year, Diamyd® received Fast Track designation for the treatment of individuals with Stage 3 Type 1 Diabetes carrying the HLA DR3-DQ2 genotype. The FDA grants Fast Track designation to facilitate the development and expedite
